Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance of [14C]-CTP-543 in Healthy Men
NCT04092712Phase 1Completed
- Sponsor
- Concert Pharmaceuticals
- Start
- Sep 2019
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of deuruxolitinib in alopecia areata, sponsored by Concert Pharmaceuticals. Primary endpoints: Percent of total radioactivity recovered in urine at Day 15, Percent of total radioactivity recovered in feces at Day 15 and 4 more. Started Sep 2019; status: completed.
02
Drugs
deuruxolitinib
03
Conditions
alopecia areata
Beyond the preview
Go deeper on NCT04092712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04092712.